Search - tctmd.com

Displaying 1 - 20 of 26

Sort: Relevancy | Date

News Daily News

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

L.A. McKeown

September 17, 2020

News Conference News LINC 2020

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

L.A. McKeown

January 28, 2020

News Conference News VEITH 2019

More Real-world Data Support Safety of Paclitaxel-Based Devices in PAD

L.A. McKeown

November 22, 2019

News Conference News VIVA 2019

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

L.A. McKeown

November 06, 2019

News Daily News

German Analysis Supports Long-term Safety of Paclitaxel-Based Therapies

L.A. McKeown

October 09, 2019

News Daily News

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Caitlin E. Cox

July 11, 2019

News Conference News SCAI 2019

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

Yael L. Maxwell

May 21, 2019

News Daily News

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

L.A. McKeown

March 15, 2019

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

L.A. McKeown

March 06, 2019

News Daily News

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

L.A. McKeown

March 01, 2019

News Conference News ISET 2019

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

Caitlin E. Cox

January 30, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Features

Top News in Endovascular Therapy: 2018

L.A. McKeown

December 28, 2018

News Conference News VIVA 2018

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

L.A. McKeown

November 06, 2018

News Conference News TCT 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

Todd Neale

September 22, 2018

News Conference News VIVA 2017

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

L.A. McKeown

September 13, 2017

News Conference News VIVA 2016

Positive Results Continue at 2 Years for Paclitaxel-Eluting PAD Stent

L.A. McKeown

September 20, 2016

News Daily News

Drug-Eluting Balloon Fails for Below-the-Knee Lesions in Critical Limb Ischemia Patients

Todd Neale

October 10, 2014

News Daily News

Drug-Eluting Balloons Reduce Restenosis, TLR in Diabetic Patients with CLI

Yael L. Maxwell

February 26, 2014

News Daily News

Zilver PTX 2-Year Results Published: Superior Safety, Efficacy vs. Angioplasty Sustained

April 12, 2013

Advertisement

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

More Real-world Data Support Safety of Paclitaxel-Based Devices in PAD

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

German Analysis Supports Long-term Safety of Paclitaxel-Based Therapies

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Top News in Endovascular Therapy: 2018

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

Positive Results Continue at 2 Years for Paclitaxel-Eluting PAD Stent

Drug-Eluting Balloon Fails for Below-the-Knee Lesions in Critical Limb Ischemia Patients

Drug-Eluting Balloons Reduce Restenosis, TLR in Diabetic Patients with CLI

Zilver PTX 2-Year Results Published: Superior Safety, Efficacy vs. Angioplasty Sustained

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content